Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

NCT05253495 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Non-hodgkin Lymphoma
Hodgkin Lymphoma

Interventions

DRUG: DOC Group B
DRUG: Pv-COMRAD 1 and 2 Group B
DRUG: Pv-R-CYM 1 and 2 Group B
DRUG: DOC Group C
DRUG: MAD CPR 1 and 2
DRUG: Pv-R CYVE 1 and 2
DRUG: Pv-R CYVE-MTX 1 and 2
DRUG: MAD CP
DRUG: Pv-Cytarabine/etoposide
DRUG: AD CP
DRUG: Bv-AVD-R 1 and 2: COHORT IIa
DRUG: Bv-NVD-R, Cycle 1-2
DRUG: Bv-NVD-R, Cycle 1-4 SER
DRUG: Bv-AVD-R
DRUG: Bv-NVD-R, Cycle 1-4 RER
DRUG: Bv-NAVD-R, Cycle 1-2
RADIATION: Involved Site Radiation Therapy

Sponsor

New York Medical College